You're viewing a public preview of Ollin Biosciences, Inc. Sign up free to access full investment history, financials, executives & more

Ollin Biosciences, Inc.

Active
Austin,  Texas (TX),  United States
Sector: Life Science Entity: Private Founded: 2023
2023
Founded
Year established
1
Transactions
Sign up to view
$2.20B
Deal Value
Sign up to view
About Ollin Biosciences, Inc.
Ollin Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. Its lead candidate is OLN324, a VEGF/Ang2 bispecific antibody also known as IBI324. Ollin licensed OLN324 from Innovent Biologics, which discovered and is being developed in collaboration with Ollin. OLN324 is aimed at diabetic macular edema (DME) and wet age-related macular degeneration (wAMD). In a randomized Phase 1b study it was compared head-to-head with Roche’s Vabysmo and showed better outcomes, and the company plans to start global Phase 3 trials in the second half of 2026. Its second program is OLN102, a bispecific antibody licensed from VelaVigo for thyroid eye disease and Graves’ disease, which is expected to enter into clinical development this year (2026). The company targets the global retina and ophthalmology markets. Founded in 2023, the company is headquartered in Austin, Texas, United States.
Investors
Current Investors
Johnson & Johnson ••••••••
Past Investors
•••••••• ••••••••
View Full Investor List
Sign up to see all current & past investors with deal dates and transaction details
Investment Details
1 Transactions
Trans. IDInvestment DateExit DateInvestor(s)Deal Size (M)Seller(s)
Access 1 Transaction
Sign up to view the full investment history — dates, deal sizes, investors & sellers
Ollin Biosciences, Inc. M&A Activity
# Company Transaction Date Close Date Sector Country
View M&A Acquisitions
Sign up to explore the full acquisition & merger history
Key Executives & Professionals
View Executives & Professionals
Sign up to access board members, senior management & key contacts
Frequently Asked Questions
What does Ollin Biosciences, Inc. do?
Ollin Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. Its lead candidate is OLN324, a VEGF/Ang2 bispecific antibody also known as IBI324. Ollin licensed OLN324 from Innovent Biologics, wh
Where is Ollin Biosciences, Inc. headquartered?
Ollin Biosciences, Inc. is headquartered in Austin, Texas (TX), United States.
When was Ollin Biosciences, Inc. founded?
Ollin Biosciences, Inc. was founded in 2023.
What sector is Ollin Biosciences, Inc. in?
Ollin Biosciences, Inc. operates in the Life Science sector.
Who are the investors in Ollin Biosciences, Inc.?
Current investors in Ollin Biosciences, Inc. include Johnson & Johnson. Sign up to AcquityData to view full investor details, deal dates and transaction history.
How many M&A transactions has Ollin Biosciences, Inc. been involved in?
Ollin Biosciences, Inc. has 1 transaction tracked on AcquityData. Sign up to view full investment history including dates, deal sizes, investors and sellers.

Unlock the full Ollin Biosciences, Inc. profile

Ownership & Investors M&A History Financials Key Executives Advisors & Lenders

Access Ollin Biosciences, Inc.'s complete ownership history, M&A activity, investors, advisors and executives in one connected platform.

Start Free Trial